Patents by Inventor Curtis Wright

Curtis Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7413749
    Abstract: A titration dosing regimen for the administration of controlled release tramadol analgesic to patients. The titration dosing regimen provides a significant reduction in the occurrence of adverse effects from the introduction of controlled released tramadol dosing, thus increasing patient compliance and medication tolerability.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: August 19, 2008
    Assignee: Purdue Pharma L.P.
    Inventors: Curtis Wright, Robert Colucci, Raymond Sanchez
  • Patent number: 7384653
    Abstract: The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is covered with a coating that is substantially insoluble in the gastrointestinal tract. In one embodiment, the adverse-effect agent is coated with an outer base-soluble layer and an inner acid-soluble layer. The therapeutic agent can be uncoated or can be coated with a coating having an outer acid-soluble layer and an inner base-soluble layer. The dosage form discourages administration of the therapeutic agent by other than oral administration.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: June 10, 2008
    Assignee: Purdue Pharma L.P.
    Inventors: Curtis Wright, IV, Anthony E. Carpanzano
  • Publication number: 20080132532
    Abstract: The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady state Cave and the steady state AUC of the first and second dosage forms are dose proportional and the single dose Cmax of the second dosage form is less than the minimum level for dose proportionality with respect to the first dosage form. The present invention also relates to methods of administering such dosage forms to a patient, as well as to kits comprising such dosage forms and instructions for administration of the dosage forms to a patient. The inventors believe that the dosage forms and methods of the present invention will lead to improved safety and patient acceptance.
    Type: Application
    Filed: August 30, 2005
    Publication date: June 5, 2008
    Inventors: Curtis Wright, Robert Colucci, Ahmed El-Tahtawy
  • Publication number: 20080054008
    Abstract: The invention relates to a device for the time-controlled dispensing of pharmaceutical compositions to a patient. The device is intended to allow multiple doses of pharmaceutical compositions to be delivered to a patient over a predetermined or programmable dosing schedule.
    Type: Application
    Filed: July 17, 2007
    Publication date: March 6, 2008
    Applicant: Javelin Pharmaceuticals, Inc.
    Inventor: Curtis Wright
  • Publication number: 20080017658
    Abstract: The invention relates to a device for the time-controlled dispensing of pharmaceutical compositions to a patient. The device is intended to allow multiple doses of pharmaceutical compositions to be delivered to a patient over a predetermined or programmable dosing schedule.
    Type: Application
    Filed: July 19, 2006
    Publication date: January 24, 2008
    Applicant: Javelin Pharmaceuticals, Inc.
    Inventor: Curtis Wright
  • Publication number: 20070232566
    Abstract: The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention.
    Type: Application
    Filed: March 22, 2007
    Publication date: October 4, 2007
    Inventors: Curtis Wright, Daniel B. Carr, Fred H. Mermelstein
  • Publication number: 20070232567
    Abstract: The present invention is directed to pharmaceutical compositions containing (a) a dosage of a non-steroidal anti-inflammatory drug (NSAID) effective to induce analgesia an anti-inflammatory effect, or an anti-pyretic effect and (b) a beta-cyclodextrin compound; wherein the dosage of the NSAID compound is less than the minimum approved dose for the route of administration. Additionally, the present invention is directed to methods for treating a mammal in need of an analgesic, an anti-inflammatory, or an anti-pyretic agent comprising administering the pharmaceutical composition of the present invention.
    Type: Application
    Filed: March 22, 2007
    Publication date: October 4, 2007
    Inventors: Curtis Wright, Daniel B. Carr, Fred H. Mermelstein
  • Patent number: 7275691
    Abstract: An indirect artillery fire control system is shown, in which a plurality of indirect artillery systems are linked with a fire direction system such that a call for fire order is communicated as a fire command to a selected indirect artillery system, with that system being selected by reason of a characteristic of that indirect artillery system.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: October 2, 2007
    Inventors: Curtis Wright, Thomas Bradley
  • Patent number: 7144587
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and a bittering agent in an effective amount to impart a bitter taste to an abuser upon administration of the dosage form after tampering.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: December 5, 2006
    Assignee: Euro-Celtique S.A.
    Inventors: Benjamin Oshlack, Robert Colucci, Curtis Wright, Christopher Breder
  • Patent number: 7141250
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of a bittering agent to impart a bitter taste to an abuser upon administration of said dosage form after tampering.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: November 28, 2006
    Assignee: Euro-Celtique S.A.
    Inventors: Benjamin Oshlack, Robert Colucci, Curtis Wright, Christopher Breder
  • Publication number: 20060194826
    Abstract: Disclosed is a pharmaceutical composition comprising from about 5 to about 20 mg of hydrocodone or a pharmaceutically acceptable salt thereof and from 0.055 to about 0.56 mg naltrexone or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 9, 2004
    Publication date: August 31, 2006
    Applicant: EURO-CELTIQUE S.A.
    Inventors: Benjamin Oshlack, Curtis Wright, Chris Breder
  • Publication number: 20060182801
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.
    Type: Application
    Filed: February 13, 2006
    Publication date: August 17, 2006
    Inventors: Christopher Breder, Benjamin Oshlack, Curtis Wright
  • Publication number: 20060039970
    Abstract: Controlled-release dosage forms comprising opioid agonist and opioid antagonist are provided. The dosage forms release the opioid antagonist and the opioid agonist in a controlled-release manner. The dosage forms may be used to provide pain relief to patients while reducing the side effects associated with opioid agonists.
    Type: Application
    Filed: November 4, 2003
    Publication date: February 23, 2006
    Inventors: Benjamin Oshlack, Curtis Wright, J. Haddox
  • Publication number: 20050181046
    Abstract: Controlled-release dosage forms comprising opioid agonist and opioid antagonist are provided. The dosage forms release the opioid antagonist and the opioid agonist in a controlled-release manner. The dosage forms may be used to provide pain relief to patients while reducing the side effects associated with opioid agonists.
    Type: Application
    Filed: November 4, 2003
    Publication date: August 18, 2005
    Inventors: Benjamin Oshlack, Curtis Wright, J. Haddox
  • Publication number: 20050095291
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.
    Type: Application
    Filed: November 4, 2003
    Publication date: May 5, 2005
    Inventors: Benjamin Oshlack, Curtis Wright, J. Haddox
  • Publication number: 20050063909
    Abstract: The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is covered with a coating that is substantially insoluble in the gastrointestinal tract. In one embodiment, the adverse-effect agent is coated with an outer base-soluble layer and an inner acid-soluble layer. The therapeutic agent can be uncoated or can be coated with a coating having an outer acid-soluble layer and an inner base-soluble layer. The dosage form discourages administration of the therapeutic agent by other than oral administration.
    Type: Application
    Filed: September 23, 2004
    Publication date: March 24, 2005
    Inventors: Curtis Wright, Anthony Carpanzano
  • Publication number: 20040259956
    Abstract: A titration dosing regimen for the administration of controlled release tramadol analgesic to patients. The titration dosing regimen provides a significant reduction in the occurrence of adverse effects from the introduction of controlled released tramadol dosing, thus increasing patient compliance and medication tolerability.
    Type: Application
    Filed: March 10, 2004
    Publication date: December 23, 2004
    Inventors: Curtis Wright, Robert Colucci, Raymond Sanchez
  • Publication number: 20040241218
    Abstract: The present invention relates to transdermal dosage form (FIG. 1-3) comprising at least one activating agent and at least one inactivating agent. The dosage form (FIG. 1-3) releases the inactivating agent upon disruption of the dosage form (FIG. 1-3) thereby preventing or hindering misuse of the active agent contained in the dosage form (FIG. 1-3).
    Type: Application
    Filed: November 20, 2003
    Publication date: December 2, 2004
    Inventors: Lino Tavares, Bruce E Reidenberg, Richard S Sackler, Curtis Wright, Mark A Alfonso, Benjamin Oshlack, James P Cassidy, Anthony E Carpanzano, Rampurna P Gullapalli, Ihor Shevchuk
  • Publication number: 20040186121
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.
    Type: Application
    Filed: October 21, 2003
    Publication date: September 23, 2004
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Publication number: 20040176402
    Abstract: Controlled-release dosage forms containing an opioid agonist; an opioid antagonist; and a controlled release material release during a dosing interval an analgesic or sub-analgesic amount of the opioid agonist along with an amount of said opioid antagonist effective to attenuate a side effect of said opioid agonist. The dosage form provides analgesia for at least about 8 hours when administered to human patients. In other embodiments, the dose of antagonist released during the dosing interval enhances the analgesic potency of the opioid agonist.
    Type: Application
    Filed: December 29, 2003
    Publication date: September 9, 2004
    Inventors: Benjamin Oshlack, Curtis Wright